-
South Africa: Important TB Drug As Effective at Lower Dose, Study Finds
spotlight, 26 July 2021
The treatment of drug-resistant forms of tuberculosis (DR-TB) has been transformed over the last decade with treatment becoming more effective, safer, and treatment duration in… Read more »
-
Africa: Three-Drug Combo 'Cures 90% of Severe TB Cases'
SciDev.Net, 21 April 2021
A three-drug regimen for treating drug-resistant TB strains cured 90 per cent of patients and cut down treatment period from about 20 months to six months, a conference heard. Read more »
-
Africa: Drug-Resistant Tuberculosis Trial Ends Enrolment After Positive Initial Data
MSF, 24 March 2021
London - A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and… Read more »
-
South Africa: 400 People in SA With Highly Drug-Resistant TB to Get New Three-Drug Regimen
spotlight, 27 January 2021
Treatment of drug-resistant forms of tuberculosis (DR-TB) in South Africa has been transformed over the last decade. Most people with DR-TB no longer have to take daily injections… Read more »
-
South Africa: Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis
TB Alliance, 10 December 2020
TB Alliance welcomes the Wits Health Consortium and the South African National Department of Health (DoH)’s announcement of an initiative to provide a new, shorter treatment… Read more »
-
TB Alliance, 4 August 2020
PRETORIA (3 August 2020)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, has been granted a conditional marketing authorisation by the… Read more »